Basal Cell Carcinoma Clinical Trial
Official title:
Dynamic Optical Coherence Tomography for Detection and Subtyping of Basal Cell
The current gold standard for diagnosing basal cell carcinoma (BCC) is the histopathological examination of biopsy specimen. However, non-invasive imaging modalities such as optical coherence tomography (OCT) may replace biopsy if BCC presence and its subtype can be established with high confidence. Subtype differentiation is crucial; while superficial BCCs (sBCC) can be treated topically, nodular (nBCC) and infiltrative BCCs (iBCC) require excision. Dynamic OCT (D-OCT) is a functionality integrated within the OCT device, enabling the visualization of vascular structures through speckle variance. Descriptive studies have unveiled vascular shapes and patterns associated with BCC and its respective subtypes. These findings suggest that D-OCT could contribute to the accuracy of BCC detection and subtyping. Yet comparative clinical studies between OCT and D-OCT are lacking. In the proposed diagnostic cohort study, we aim to assess whether D-OCT assessment is superior to OCT in terms of accuracy for BCC detection and subtyping.
Status | Not yet recruiting |
Enrollment | 424 |
Est. completion date | December 31, 2024 |
Est. primary completion date | July 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18+ years - Lesions suspect for non-melanoma skin cancer or premalignancy - Patient underwent D-OCT scan and biopsy conform regular care Exclusion Criteria: - Patient unable to sign informed consent. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic accuracy for BCC detection on D-OCT assessment | We will evaluate the ability of OCT assessors to discriminate BCC from non-BCC using OCT without and with dynamic functionality. The diagnostic certainty for BCC detection will be expressed on a five-point confidence scale. A high confidence score (confidence score=4) is considered a positive OCT test results. In these cases, biopsy could effectively be omitted. Lower confidence scores (confidence score=3) are considered negative OCT test results as in these cases, biopsy remains necessary for a definitive or alternative diagnosis. The primary outcome of interest is the sensitivity of a high confidence BCC diagnosis because we want to evaluate whether the dynamic functionality increases the proportion of correctly classified BCCs. | Measured before December 31st 2024 | |
Secondary | Diagnostic accuracy for BCC subtyping on D-OCT assessment | We will evaluate the ability of OCT assessors to discriminate each individual BCC subtype from the other two subtypes using OCT without and with dynamic functionality. Cases that resulted in a high confidence diagnosis (confidence score=4) will be included in the analyses. Three analyses will be performed to calculate the sensitivity to detect sBCC, nBCC or iBCC and the specificity to identify non-sBCC, non-nBCC or non-iBCC subtypes using histopathology as reference test. In this respect, sensitivity is defined as the proportion of a specific BCC subtype, that is correctly classified as such by the OCT assessor (i.e. sBCC, nBCC or iBCC), whereas specificity is defined as the proportion of the other two subtypes that is correctly classified as such (i.e sBCC/nBCC, sBCC/iBCC or nBCC/iBCC). The primary outcome of interest is the sensitivity. We want to evaluate whether the dynamic functionality increases the proportion of correctly classified subtypes . | Measured before December 31st 2024 | |
Secondary | Diagnostic value of vascular structures and patterns | Diagnostic odds ratios (DORs ) are used to identify subsets of vascular features and patterns that can be used to accurately discriminate BCC subtypes. The histopathological subtype (i.e. sBCC, nBCC, iBCC ) vs. other subtypes (i.e sBCC/nBCC, sBCC/iBCC, nBCC/iBCC) will be used as the dependent variable. A DOR >1 indicates that the presence of a vascular feature or pattern is indicative for the presence of the respective BCC subtype. | Measured before December 31st 2024 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04552990 -
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT04229277 -
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
|
N/A | |
Completed |
NCT05608902 -
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
|
||
Completed |
NCT05077033 -
Intratumoral phIL12 GET
|
Phase 1 | |
Active, not recruiting |
NCT04928222 -
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04929535 -
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment
|
Phase 2 | |
Completed |
NCT02662244 -
Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
|
N/A | |
Completed |
NCT00959647 -
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
|
Phase 2 | |
Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
Completed |
NCT00473343 -
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT06024629 -
cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
|
||
Not yet recruiting |
NCT05324202 -
New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management
|
N/A | |
Withdrawn |
NCT04099446 -
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
|
||
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Completed |
NCT01260987 -
Fractional CO2 Laser Assisted Photodynamic Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT01201915 -
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01208831 -
An East Asian Study of LDE225
|
Phase 1 | |
Completed |
NCT01014819 -
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
|
N/A | |
Completed |
NCT00472043 -
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma
|
Phase 3 |